Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization

JACC: Heart Failure

Volumn 7, Issue 1, 2019, Pages 1-12

  Bhagat, Aditi A ^a   Greene, Stephen J ^b,c   Vaduganathan, Muthiah ^d   Fonarow, Gregg C ^e   Butler, Javed ^f  

^a STONY BROOK UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

heart failure; medical decision making; medication adherence; medication discontinuation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; METOPROLOL; METOPROLOL SUCCINATE; MINERALOCORTICOID ANTAGONIST; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE; AMINOBUTYRIC ACID DERIVATIVE; SACUBITRIL-VALSARTAN; TETRAZOLE DERIVATIVE;

ACUTE KIDNEY FAILURE; BRADYCARDIA; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DIZZINESS; DRUG TOLERABILITY; EDEMA; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART INFARCTION; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; MEDICAL DECISION MAKING; PATIENT CARE; POPULATION RISK; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT WITHDRAWAL; CLINICAL DECISION MAKING; DEPRESCRIPTION; DRUG SUBSTITUTION; HEART STROKE VOLUME; MEDICATION COMPLIANCE; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL DECISION-MAKING; DEPRESCRIPTIONS; DRUG SUBSTITUTION; HEART FAILURE; HOSPITALIZATION; HUMANS; MEDICATION ADHERENCE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; STROKE VOLUME; TETRAZOLES;

EID: 85059496909     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2018.06.011     Document Type: Review

References (40)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 62 (2013), 1495–1539.
2. Krantz, M.J., Ambardekar, A.V., Kaltenbach, L., et al. Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get with the Guidelines-Heart Failure). Am J Cardiol 107 (2011), 1818–1823.
3. Gattis, W.A., O'Connor, C.M., Gallup, D.S., et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 43 (2004), 1534–1541.
4. Krantz, M.J., Havranek, E.P., Haynes, D.K., Smith, I., Bucher-Bartelson, B., Long, C.S., Inpatient initiation of β-blockade plus nurse management in vulnerable heart failure patients: a randomized study. J Card Fail 14 (2008), 303–309.
5. Hernandez, A.F., Hammill, B.G., O'Connor, C.M., Schulman, K.A., Curtis, L.H., Fonarow, G.C., Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 53 (2009), 184–192.
6. Fonarow, G.C., Abraham, W.T., Albert, N.M., et al. Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 153 (2007), 82.e1–82.e11.
7. Fonarow, G.C., Abraham, W.T., Albert, N.M., et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 52 (2008), 190–199.
8. Gottlieb, S.S., Fisher, M.L., Kjekshus, J., et al. Tolerability of beta-blocker initiation and titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Circulation 105 (2002), 1182–1188.
9. Krum, H., Roecker, E.B., Mohacsi, P., et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 289 (2003), 712–718.
10. Gilstrap, L.G., Fonarow, G.C., Desai, A.S., et al. Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J Am Heart Assoc, 6, 2017 pii:e004675.
11. Sanam, K., Bhatia, V., Bajaj, N.S., et al. Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure. Am J Med 129 (2016), 1067–1073.
12. Siddiqui, M., Sanders, P.W., Arora, G., et al. Use of ACE inhibitors or angiotensin receptor blockers is associated with a significantly lower risk of 30-day all-cause and heart failure readmissions and all-cause mortality in older Medicare beneficiaries hospitalized for heart failure developing acute kidney injury (abstr). Circulation, 132, 2015, A19094.
13. Pitt, B., White, H., Nicolau, J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 (2005), 425–431.
14. Brown, K., Chee, J., Kyung, S., Vettichira, B., Papadimitriou, L., Butler, J., Mineralocorticoid receptor antagonism in acute heart failure. Curr Treat Options Cardiovasc Med, 17, 2015, 402.
15. Ferreira, J.P., Santos, M., Almeida, S., Marques, I., Bettencourt, P., Carvalho, H., Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med 25 (2014), 67–72.
16. Gao, X., Peng, L., Adhikari, C.M., Lin, J., Zuo, Z., Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 13 (2007), 170–177.
17. Butler, J., Anstrom, K.J., Felker, G.M., et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol 2 (2017), 950–958.
18. Maisel, A., Xue, Y., van Veldhuisen, D.J., et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol 114 (2014), 737–742.
19. Hamaguchi, S., Kinugawa, S., Tsuchihashi-Makaya, M., et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J 160 (2010), 1156–1162.
20. Lam, P.H., Dooley, D.J., Inampudi, C., et al. Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone. Int J Cardiol 227 (2017), 462–466.
21. Hernandez, A.F., Mi, X., Hammill, B.G., et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA 308 (2012), 2097–2107.
22. Curtis, L.H., Mi, X., Qualls, L.G., et al. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J 165 (2013), 979–986.e1.
23. Fonarow, G.C., Albert, N.M., Curtis, A.B., et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 122 (2010), 585–596.
24. Butler, J., Young, J.B., Abraham, W.T., et al. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol 47 (2006), 2462–2469.
25. Fonarow, G.C., Abraham, W.T., Albert, N.M., et al. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. J Card Fail 13 (2007), 722–731.
26. Kane, J.A., Kim, J.K., Haidry, S.A., Salciccioli, L., Lazar, J., Discontinuation/dose reduction of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers during acute decompensated heart failure in African-American patients with reduced left-ventricular ejection fraction. Cardiology 137 (2017), 121–125.
27. McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
28. Desai, A.S., Claggett, B.L., Packer, M., et al. Influence of sacubitril/valsartan (LCZ696) on 30-Day readmission after heart failure hospitalization. J Am Coll Cardiol 68 (2016), 241–248.
29. Simpson, J., Jhund, P.S., Silva Cardoso, J., et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol 66 (2015), 2059–2071.
30. Luo, N., Fonarow, G.C., Lippmann, S.J., et al. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines–Heart Failure (GWTG-HF). J Am Coll Cardiol HF 5 (2017), 305–309.
31. Fonarow, G.C., Hernandez, A.F., Solomon, S.D., Yancy, C.W., Potential mortality reduction with optimal implementation of angiotensin receptor neprilysin inhibitor therapy in heart failure. JAMA Cardiol 1 (2016), 714–717.
32. Velazquez, E.J., Morrow, D.A., DeVore, A.D., et al. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J 198 (2018), 145–151.
33. Gheorghiade, M., Pang, P.S., Acute heart failure syndromes. J Am Coll Cardiol 53 (2009), 557–573.
34. Vaduganathan, M., Butler, J., Pitt, B., Gheorghiade, M., Contemporary drug development in heart failure: call for hemodynamically neutral therapies. Circ Heart Fail 8 (2015), 826–831.
35. Fonarow, G.C., Abraham, W.T., Albert, N.M., et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol 102 (2008), 1524–1529.
36. Rossignol, P., Cleland, J.G., Bhandari, S., et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients post myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 125 (2012), 271–279.
37. Yancy, C.W., Januzzi, J.L. Jr., Allen, L.A., et al. 2017 ACC Expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 71 (2018), 201–230.
38. Ambrosy, A.P., Butler, J., Gheorghiade, M., Clinical trials in acute heart failure: beginning of the end or end of the beginning?. Eur J Heart Fail 19 (2017), 1358–1360.
39. Pitt, B., Remme, W., Zannad, F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003), 1309–1321.
40. Senni, M., McMurray, J.J., Wachter, R., et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur Heart J Fail 18 (2016), 1193–1202.